Comparing progression biomarkers in clinical trials of early Alzheimer's disease.
Nicholas C CullenHenrik ZetterbergPhilip S InselBob OlssonUlf Andreassonnull nullKaj BlennowOskar HanssonNiklas Mattsson-CarlgrenPublished in: Annals of clinical and translational neurology (2020)
MRI measures had properties that made them preferable to cognition and pNFL as outcome measures in clinical trials of early AD, regardless of cognitive status. However, pNfL and cognition can still be effective depending on inclusion criteria, sampling frequency, and response to therapy. Future trials will help to understand how sensitive pNfL and MRI are to detect downstream effects on neurodegeneration of drugs targeting amyloid and tau pathology in AD.
Keyphrases
- clinical trial
- contrast enhanced
- magnetic resonance imaging
- mild cognitive impairment
- white matter
- diffusion weighted imaging
- cognitive decline
- phase ii
- computed tomography
- stem cells
- open label
- cancer therapy
- randomized controlled trial
- multiple sclerosis
- cerebrospinal fluid
- drug delivery
- smoking cessation
- replacement therapy
- drug induced